These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 22943170)
1. Long-term stability of quercetin nanocrystals prepared by different methods. Kakran M; Shegokar R; Sahoo NG; Gohla S; Li L; Müller RH J Pharm Pharmacol; 2012 Oct; 64(10):1394-402. PubMed ID: 22943170 [TBL] [Abstract][Full Text] [Related]
2. Fabrication of quercetin nanocrystals: comparison of different methods. Kakran M; Shegokar R; Sahoo NG; Shaal LA; Li L; Müller RH Eur J Pharm Biopharm; 2012 Jan; 80(1):113-21. PubMed ID: 21896330 [TBL] [Abstract][Full Text] [Related]
3. Effect of four different size reduction methods on the particle size, solubility enhancement and physical stability of nicergoline nanocrystals. Martena V; Shegokar R; Di Martino P; Müller RH Drug Dev Ind Pharm; 2014 Sep; 40(9):1199-205. PubMed ID: 23815299 [TBL] [Abstract][Full Text] [Related]
4. Precipitation-lyophilization-homogenization (PLH) for preparation of clarithromycin nanocrystals: influencing factors on physicochemical properties and stability. Morakul B; Suksiriworapong J; Leanpolchareanchai J; Junyaprasert VB Int J Pharm; 2013 Nov; 457(1):187-96. PubMed ID: 24076396 [TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of quercetin nanocrystals. Sahoo NG; Kakran M; Shaal LA; Li L; Müller RH; Pal M; Tan LP J Pharm Sci; 2011 Jun; 100(6):2379-90. PubMed ID: 21491450 [TBL] [Abstract][Full Text] [Related]
6. Preparation of a chemically stable quercetin formulation using nanosuspension technology. Gao L; Liu G; Wang X; Liu F; Xu Y; Ma J Int J Pharm; 2011 Feb; 404(1-2):231-7. PubMed ID: 21093559 [TBL] [Abstract][Full Text] [Related]
7. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. Teeranachaideekul V; Junyaprasert VB; Souto EB; Müller RH Int J Pharm; 2008 Apr; 354(1-2):227-34. PubMed ID: 18242898 [TBL] [Abstract][Full Text] [Related]
8. Comminution of ibuprofen to produce nano-particles for rapid dissolution. Plakkot S; de Matas M; York P; Saunders M; Sulaiman B Int J Pharm; 2011 Aug; 415(1-2):307-14. PubMed ID: 21683776 [TBL] [Abstract][Full Text] [Related]
9. Nanocrystals: comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches. Salazar J; Ghanem A; Müller RH; Möschwitzer JP Eur J Pharm Biopharm; 2012 May; 81(1):82-90. PubMed ID: 22233547 [TBL] [Abstract][Full Text] [Related]
10. Preparation of azithromycin nanosuspensions by reactive precipitation method. Hou CD; Wang JX; Le Y; Zou HK; Zhao H Drug Dev Ind Pharm; 2012 Jul; 38(7):848-54. PubMed ID: 22092042 [TBL] [Abstract][Full Text] [Related]
11. Production and characterization of a spray-dried hydroxypropyl-beta-cyclodextrin/quercetin complex. Zheng Y; Chow AH Drug Dev Ind Pharm; 2009 Jun; 35(6):727-34. PubMed ID: 19514988 [TBL] [Abstract][Full Text] [Related]
12. Characterization and evaluation in vivo of baicalin-nanocrystals prepared by an ultrasonic-homogenization-fluid bed drying method. Shi-Ying J; Jin H; Shi-Xiao J; Qing-Yuan L; Jin-Xia B; Chen HG; Rui-Sheng L; Wei W; Hai-Long Y Chin J Nat Med; 2014 Jan; 12(1):71-80. PubMed ID: 24484600 [TBL] [Abstract][Full Text] [Related]
13. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)--effects of formulation parameters on physicochemical stability. Teeranachaideekul V; Müller RH; Junyaprasert VB Int J Pharm; 2007 Aug; 340(1-2):198-206. PubMed ID: 17482778 [TBL] [Abstract][Full Text] [Related]
14. Comparison of different methods for preparation of a stable riccardin D formulation via nano-technology. Liu G; Zhang D; Jiao Y; Zheng D; Liu Y; Duan C; Jia L; Zhang Q; Lou H Int J Pharm; 2012 Jan; 422(1-2):516-22. PubMed ID: 22119965 [TBL] [Abstract][Full Text] [Related]
15. Preparation and in vitro/in vivo evaluation of fenofibrate nanocrystals. Zuo B; Sun Y; Li H; Liu X; Zhai Y; Sun J; He Z Int J Pharm; 2013 Oct; 455(1-2):267-75. PubMed ID: 23876497 [TBL] [Abstract][Full Text] [Related]
16. Is the amorphous fraction of a dried nanosuspension caused by milling or by drying? A case study with Naproxen and Cinnarizine. Kayaert P; Van den Mooter G Eur J Pharm Biopharm; 2012 Aug; 81(3):650-6. PubMed ID: 22579733 [TBL] [Abstract][Full Text] [Related]
17. A novel surface modified nitrendipine nanocrystals with enhancement of bioavailability and stability. Quan P; Shi K; Piao H; Piao H; Liang N; Xia D; Cui F Int J Pharm; 2012 Jul; 430(1-2):366-71. PubMed ID: 22531846 [TBL] [Abstract][Full Text] [Related]
18. Kinetic solubility and dissolution velocity of rutin nanocrystals. Mauludin R; Müller RH; Keck CM Eur J Pharm Sci; 2009 Mar; 36(4-5):502-10. PubMed ID: 19130880 [TBL] [Abstract][Full Text] [Related]
19. Influence of particle size and preparation methods on the physical and chemical stability of amorphous simvastatin. Zhang F; Aaltonen J; Tian F; Saville DJ; Rades T Eur J Pharm Biopharm; 2009 Jan; 71(1):64-70. PubMed ID: 18703139 [TBL] [Abstract][Full Text] [Related]
20. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation. Chieng N; Aaltonen J; Saville D; Rades T Eur J Pharm Biopharm; 2009 Jan; 71(1):47-54. PubMed ID: 18644443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]